JP2024540435A - 第ＸＩ／ＸＩａ因子抗体の投薬レジメン - Google Patents

第ＸＩ／ＸＩａ因子抗体の投薬レジメン Download PDF

Info

Publication number
JP2024540435A
JP2024540435A JP2024527544A JP2024527544A JP2024540435A JP 2024540435 A JP2024540435 A JP 2024540435A JP 2024527544 A JP2024527544 A JP 2024527544A JP 2024527544 A JP2024527544 A JP 2024527544A JP 2024540435 A JP2024540435 A JP 2024540435A
Authority
JP
Japan
Prior art keywords
antibody
seq
chain variable
variable region
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024527544A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024540435A5 (https=
Inventor
デブラ エー． フリードホルム，
ダニエル エム． ブルームフィールド，
ロイストン ジェイ． グラスプール，
ジョナサン イー． フリーマン，
ヤセル クデル，
Original Assignee
アントス セラピューティクス， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アントス セラピューティクス， インコーポレイテッド filed Critical アントス セラピューティクス， インコーポレイテッド
Publication of JP2024540435A publication Critical patent/JP2024540435A/ja
Publication of JP2024540435A5 publication Critical patent/JP2024540435A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2024527544A 2021-11-18 2022-11-18 第ＸＩ／ＸＩａ因子抗体の投薬レジメン Pending JP2024540435A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202163281024P 2021-11-18 2021-11-18
US63/281,024 2021-11-18
US202163287633P 2021-12-09 2021-12-09
US63/287,633 2021-12-09
US202263355314P 2022-06-24 2022-06-24
US63/355,314 2022-06-24
PCT/US2022/080131 WO2023092062A1 (en) 2021-11-18 2022-11-18 Dosing regimens of factor xi/xia antibodies

Publications (2)

Publication Number Publication Date
JP2024540435A true JP2024540435A (ja) 2024-10-31
JP2024540435A5 JP2024540435A5 (https=) 2025-11-28

Family

ID=86397863

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024527544A Pending JP2024540435A (ja) 2021-11-18 2022-11-18 第ＸＩ／ＸＩａ因子抗体の投薬レジメン

Country Status (8)

Country Link
US (1) US20240294669A1 (https=)
EP (1) EP4433088A4 (https=)
JP (1) JP2024540435A (https=)
KR (1) KR20240109269A (https=)
CA (1) CA3234626A1 (https=)
IL (1) IL311801A (https=)
TW (1) TW202334239A (https=)
WO (1) WO2023092062A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230071973A1 (en) * 2019-12-20 2023-03-09 Anthos Therapeutics, Inc. Pharmaceutical formulations and dosage regimens for factor xi/xia antibodies
US20250388679A1 (en) * 2024-06-20 2025-12-25 argenx BV Subcutaneous fcrn antagonist formulations and methods of use thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6321886B2 (ja) * 2014-05-15 2018-05-09 エンジーケム ライフサイエンシーズ コーポレーションＥｎｚｙｃｈｅｍ Ｌｉｆｅｓｃｉｅｎｃｅｓ Ｃｏｒｐｏｒａｔｉｏｎ 白血球減少症及び血小板減少症に対する治療方法
UY36751A (es) * 2015-06-26 2017-01-31 Novartis Ag Anticuerpos de factor xi y métodos de uso
US11066481B2 (en) * 2015-07-23 2021-07-20 The Regents Of The University Of California Antibodies to coagulation factor XIa and uses thereof
TW201802121A (zh) * 2016-05-25 2018-01-16 諾華公司 抗因子XI/XIa抗體之逆轉結合劑及其用途
EP3713965A1 (en) * 2017-11-22 2020-09-30 Novartis AG Reversal binding agents for anti-factor xi/xia antibodies and uses thereof
US20230071973A1 (en) * 2019-12-20 2023-03-09 Anthos Therapeutics, Inc. Pharmaceutical formulations and dosage regimens for factor xi/xia antibodies
TW202405022A (zh) * 2022-06-24 2024-02-01 美商安瑟斯治療公司 與抗因子ｘｉ／因子ｘｉａ抗體之組合療法

Also Published As

Publication number Publication date
US20240294669A1 (en) 2024-09-05
WO2023092062A1 (en) 2023-05-25
KR20240109269A (ko) 2024-07-10
EP4433088A1 (en) 2024-09-25
CA3234626A1 (en) 2023-05-25
EP4433088A4 (en) 2026-01-14
IL311801A (en) 2024-05-01
TW202334239A (zh) 2023-09-01

Similar Documents

Publication Publication Date Title
KR102576012B1 (ko) 고농도 항-c5 항체 제형
JP7500662B2 (ja) 抗第ＸＩ／ＸＩａ因子抗体による処置法
US20240294669A1 (en) Dosing regimens of factor xi/xia antibodies
TW201722993A (zh) 凝血因子ｘｉ抗體及使用方法
TWI844571B (zh) 使用抗血管內皮生長因子（ｖｅｇｆ）抗體與抗組織因子（ｔｆ）抗體－藥物共軛體之組合以治療癌症之方法
JP2026048712A (ja) 第ＸＩ／ＸＩａ因子抗体の医薬製剤および投薬レジメン
KR20180094028A (ko) 혈장 칼리크레인 저해제 및 유전성 혈관부종 발작을 치료하기 위한 이의 용도
JP2019521978A (ja) 抗凝固因子ｘｉ抗体
BR112019012667A2 (pt) Anticorpos do fator xi e métodos de uso
JP7558306B2 (ja) 疼痛の治療における使用のためのＴＧＦ－α及びエピレグリンに結合する抗体
BR112021010999A2 (pt) Uso de anticorpo pd-l1 de articulação do complexo de proteína il-15 para tratamento de doenças tumorais
WO2018223958A1 (zh) 一种含c-Met抗体药物偶联物的药物组合物及其用途
JP2025523506A (ja) 抗第ｘｉ因子／第ｘｉａ因子抗体との併用療法
JP2024544057A (ja) 血栓塞栓性疾患を予防及び／又は治療する方法
AU2018361975A1 (en) Method of treating tendinopathy using interleukin-17 (IL-17) antagonists
CN118302196A (zh) 因子XI/XIa抗体的给药方案
TW202114734A (zh) Il-17拮抗劑治療自身免疫疾病的方法
WO2025166169A1 (en) Compositions, doses, and methods for treatment of c1s mediated diseases and disorders
CN115531531A (zh) 抗人vegf抗体和化疗联用在制备治疗结直肠癌药物中的用途
BR112017027778B1 (pt) Anticorpo anti-fxi e/ou anti-fxia ativado isolado, usos do mesmo, composição farmacêutica, medicamento, sequência de ácido nucleico, e vetor

Legal Events

Date Code Title Description
RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20250702

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20250710

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251118

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20251118